Gold has topped $4,200. Here’s why Yardeni thinks the rally could go even higher.
PORTLAND, Maine - ImmuCell Corporation (NASDAQ:ICCC) announced Monday it has appointed Olivier te Boekhorst as its next President and CEO, effective November 1, 2025. The appointment comes as the company shows strong momentum, with InvestingPro data showing a remarkable 70% stock return over the past year and revenue growth of 22% in the last twelve months.
Te Boekhorst currently serves as an Operating Partner at ARCHIMED, a global healthcare investment firm, and as Chair of the Board at SeqCenter. He previously held leadership positions at IDEXX Laboratories from 2004 to 2022, where he led the livestock and dairy diagnostics divisions.
Michael F. Brigham, ImmuCell’s current President and CEO, will transition to a Special Advisor role for at least two months following te Boekhorst’s start date. Brigham will continue to serve on the company’s Board of Directors until the next Annual Meeting of Stockholders.
"Olivier brings to the Company a depth of experience and industry contacts that we expect will be very valuable," said Brigham in the company’s press release.
As part of his employment agreement, te Boekhorst will receive stock options to purchase 76,673 shares of ImmuCell common stock granted on September 16, 2025, with an exercise price of $5.90 per share. A second grant of up to 85,000 shares will be made after he begins employment. Both grants will vest in three equal annual increments.
ImmuCell manufactures First Defense, a product providing immunity to newborn dairy and beef calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows.
The company describes itself as focused on creating "scientifically proven and practical products that improve the health and productivity of dairy and beef cattle" without traditional antibiotics.
In other recent news, ImmuCell Corporation reported a strong performance for the second quarter of 2025, with notable growth in product sales and improved gross margins. Despite these positive results, the company’s earnings per share (EPS) of $0.06 fell short of market expectations. This earnings announcement is a key development for investors, as it highlights the company’s ongoing financial trajectory. The recent earnings report underscores the importance of meeting market projections, which can significantly impact investor sentiment. Although ImmuCell’s product sales have shown robust growth, the earnings miss has drawn attention from market analysts. These developments are essential for investors to consider as they assess the company’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.